サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1360313

細胞分析市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Cell Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 166 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
細胞分析市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年
出版日: 2023年08月22日
発行: Transparency Market Research
ページ情報: 英文 166 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞分析市場- レポートの範囲

世界の細胞分析市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの細胞分析の世界市場の収益を掲載しています。また、2023年から2031年までの世界の細胞分析市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、細胞分析市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書を参照することが含まれます。

市場スナップショット
2023年の市場価値 190億米ドル
2031年の市場価値 424億米ドル
CAGR 9.2%

このレポートは、世界の細胞分析市場の競合情勢を詳しく掘り下げています。世界の細胞分析市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の細胞分析市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 市場概要

  • 概要
  • 市場力学
  • 主要なバイオテクノロジー企業と製薬企業の治療分野別の研究開発費の概要

第4章 世界の細胞分析市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：エンドユーザー別、2017-2031
    • バイオテクノロジーおよび製薬会社
    • 学術界
    • 化粧品産業
    • 受託調査機関
    • 受託開発・製造組織

第5章 世界市場の分析と予測：治療領域別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：治療領域別、2015-2031
    • 腫瘍学および腫瘍免疫学
      • 低分子
      • タンパク質ベースの治療法
      • 細胞治療
      • 核酸医薬品
    • 心血管疾患および代謝疾患
      • 低分子
      • タンパク質ベースの治療法
      • 細胞治療
      • 核酸医薬品
    • 免疫学
      • 低分子
      • タンパク質ベースの治療法
      • 細胞治療
      • 核酸医薬品
    • 希少疾患
      • 低分子
      • タンパク質ベースの治療法
      • 細胞治療
      • 核酸医薬品
    • 神経疾患
      • 低分子
      • タンパク質ベースの治療法
      • 細胞治療
      • 核酸医薬品
    • その他
      • 低分子
      • タンパク質ベースの治療法
      • 細胞治療
      • 核酸医薬品

第6章 世界市場の分析と予測：テクノロジー別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：テクノロジー別、2017-2031
    • フローサイトメトリー
    • 画像ベースのサイトメトリー
    • 生化学的アッセイ
    • 質量分析法

第7章 世界市場の分析と予測：ワークプレイス別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：ワークプレイス別、2017-2031
    • ターゲットの特定
    • ヒット生成とリードの特定
    • リードの最適化
    • インビトロ前臨床研究
    • インビボ前臨床研究
    • 臨床研究

第8章 世界市場の分析と予測：国/地域別

  • 主な調査結果
  • 市場金額予測：国/地域別、2017-2031
    • 米国
    • 欧州
    • 中国
    • 世界のその他の地域

第9章 米国の細胞分析市場の分析と予測

第10章 欧州の細胞分析市場の分析と予測

第11章 中国の細胞分析市場の分析と予測

第12章 世界のその他の地域の細胞分析市場の分析と予測

図表

List of Tables

  • Table 01: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (1/4)
  • Table 02: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/4)
  • Table 03: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/3)
  • Table 04: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (4/4)
  • Table 05: Top 15 Origins of Pipeline Drugs
  • Table 06: Global Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 07: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 08: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 09: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 10: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
  • Table 16: Global Cell Analysis Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 17: U.S. Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 18: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 19: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 20: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 21: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 22: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 23: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 24: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 25: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 26: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
  • Table 27: Europe Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 28: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 29: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 30: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 31: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 32: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 33: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 34: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 35: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 36: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
  • Table 37: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 38: China Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 39: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 40: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 41: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 42: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 43: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 44: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 45: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 46: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 47: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
  • Table 48: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 49: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 50: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 51: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 52: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 53: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 54: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 55: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 56: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 57: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

List of Figures

  • Figure 01: Major R&D spending therapeutic areas, by companies
  • Figure 02: Biological versus non-biological drugs as a % of pipeline
  • Figure 03: Ongoing rise of gene and cell therapy
  • Figure 04: Global Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 05: Global Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 06: Global Cell Analysis Market (US$ Mn), by Biotechnology & Pharmaceutical Companies, 2017-2031
  • Figure 07: Global Cell Analysis Market (US$ Mn), by Academia, 2017-2031
  • Figure 08: Global Cell Analysis Market (US$ Mn), by Cosmetic Industry, 2017-2031
  • Figure 09: Global Cell Analysis Market (US$ Mn), by Contract Research Organizations, 2017-2031
  • Figure 10: Global Cell Analysis Market (US$ Mn), by Contract Development and Manufacturing Organizations, 2017-2031
  • Figure 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Oncology & Immune-oncology, 2017-2031
  • Figure 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Cardiovascular & Metabolic Diseases, 2017-2031
  • Figure 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Immunology, 2017-2031
  • Figure 16: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Rare Diseases, 2017-2031
  • Figure 17: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Neurological Diseases, 2017-2031
  • Figure 18: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Others, 2017-2031
  • Figure 19: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 20: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 21: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Flow Cytometry, 2017-2031
  • Figure 22: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Image-based Cytometry/Microscopy, 2017-2031
  • Figure 23: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Biochemical Assays, 2017-2031
  • Figure 24: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Mass Spectrometry, 2017-2031
  • Figure 25: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace, 2022 and 2031
  • Figure 26: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
  • Figure 27: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Target Identification, 2017-2031
  • Figure 28: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Hit Generation & Lead Identification, 2017-2031
  • Figure 29: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Lead Optimization, 2017-2031
  • Figure 30: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vitro Preclinical Studies, 2017-2031
  • Figure 31: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vivo Preclinical Studies, 2017-2031
  • Figure 32: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Clinical Studies, 2017-2031
  • Figure 33: Global Cell Analysis Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 34: Global Cell Analysis Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 35: U.S. Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 36: U.S. Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 37: U.S. Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 38: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 39: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 40: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 41: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 42: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
  • Figure 43: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
  • Figure 44: Europe Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 45: Europe Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 46: Europe Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 47: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 48: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 49: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 50: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 51: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
  • Figure 52: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
  • Figure 53: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 54: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 55: China Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 56: China Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 57: China Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 58: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 59: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 60: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 61: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 62: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
  • Figure 63: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
  • Figure 64: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 65: Rest of the World Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 66: Rest of the World Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 67: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 68: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 69: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 70: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 71: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
  • Figure 72: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
目次
Product Code: TMRGL12221

Cell Analysis Market - Scope of Report

TMR's report on the global cell analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell analysis market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell analysis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell analysis market.

Market Snapshot
Market Value in 2023US$ 19 Bn
Market Value in 2031US$ 42.4 Bn
CAGR9.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell analysis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell analysis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell analysis market.

The report delves into the competitive landscape of the global cell analysis market. Key players operating in the global cell analysis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell analysis market profiled in this report.

Key Questions Answered in Global Cell Analysis Market Report:

  • What is the sales/revenue generated by cell analysis across all regions during the forecast period?
  • What are the opportunities in the global cell analysis market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cell Analysis Market - Research Objectives and Research Approach

The comprehensive report on the global cell analysis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell analysis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell analysis market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Key Research Objectives

2. Assumptions and Research Methodology

3. Market Overview

  • 3.1. Overview
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
  • 3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area
    • 3.3.1. Top 15 Origins of Pipeline Drugs
    • 3.3.2. Biological versus non-biological drugs as a % of pipeline
    • 3.3.3. Ongoing rise of gene and cell therapy

4. Global Cell Analysis Market Analysis and Forecast, by End-user

  • 4.1. Introduction & Definition
  • 4.2. Key Findings/Developments
  • 4.3. Market Value Forecast, by End-user, 2017-2031
    • 4.3.1. Biotechnology & Pharmaceutical Companies
    • 4.3.2. Academia
    • 4.3.3. Cosmetic Industry
    • 4.3.4. Contract Research Organizations
    • 4.3.5. Contract Development and Manufacturing Organizations

5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area

  • 5.1. Introduction & Definition
  • 5.2. Key Findings/Developments
  • 5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
    • 5.3.1. Oncology & Immune-oncology
      • 5.3.1.1. Small Molecules
      • 5.3.1.2. Protein-based Therapeutics
      • 5.3.1.3. Cell Therapy
      • 5.3.1.4. Nucleic Acid-based Drugs
    • 5.3.2. Cardiovascular & Metabolic Diseases
      • 5.3.2.1. Small Molecules
      • 5.3.2.2. Protein-based Therapeutics
      • 5.3.2.3. Cell Therapy
      • 5.3.2.4. Nucleic Acid-based Drugs
    • 5.3.3. Immunology
      • 5.3.3.1. Small Molecules
      • 5.3.3.2. Protein-based Therapeutics
      • 5.3.3.3. Cell Therapy
      • 5.3.3.4. Nucleic Acid-based Drugs
    • 5.3.4. Rare Diseases
      • 5.3.4.1. Small Molecules
      • 5.3.4.2. Protein-based Therapeutics
      • 5.3.4.3. Cell Therapy
      • 5.3.4.4. Nucleic Acid-based Drugs
    • 5.3.5. Neurological Diseases
      • 5.3.5.1. Small Molecules
      • 5.3.5.2. Protein-based Therapeutics
      • 5.3.5.3. Cell Therapy
      • 5.3.5.4. Nucleic Acid-based Drugs
    • 5.3.6. Others
      • 5.3.6.1. Small Molecules
      • 5.3.6.2. Protein-based Therapeutics
      • 5.3.6.3. Cell Therapy
      • 5.3.6.4. Nucleic Acid-based Drugs

6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Technology, 2017-2031
    • 6.3.1. Flow Cytometry
    • 6.3.2. Image-based Cytometry
    • 6.3.3. Biochemical Assays
    • 6.3.4. Mass Spectrometry

7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Workplace, 2017-2031
    • 7.3.1. Target Identification
    • 7.3.2. Hit Generation & Lead Identification
    • 7.3.3. Lead Optimization
    • 7.3.4. In Vitro Preclinical Studies
    • 7.3.5. In Vivo Preclinical Studies
    • 7.3.6. Clinical Studies

8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Country/Region, 2017-2031
    • 8.2.1. U.S.
    • 8.2.2. Europe
    • 8.2.3. China
    • 8.2.4. Rest of the World

9. U.S. Cell Analysis Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by End-user, 2017-2031
    • 9.2.1. Biotechnology & Pharmaceutical Companies
    • 9.2.2. Academia
    • 9.2.3. Cosmetic Industry
    • 9.2.4. Contract Research Organizations
    • 9.2.5. Contract Development and Manufacturing Organizations
  • 9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
    • 9.3.1. Oncology & Immune-oncology
      • 9.3.1.1. Small Molecules
      • 9.3.1.2. Protein-based Therapeutics
      • 9.3.1.3. Cell Therapy
      • 9.3.1.4. Nucleic Acid-based Drugs
    • 9.3.2. Cardiovascular & Metabolic Diseases
      • 9.3.2.1. Small Molecules
      • 9.3.2.2. Protein-based Therapeutics
      • 9.3.2.3. Cell Therapy
      • 9.3.2.4. Nucleic Acid-based Drugs
    • 9.3.3. Immunology
      • 9.3.3.1. Small Molecules
      • 9.3.3.2. Protein-based Therapeutics
      • 9.3.3.3. Cell Therapy
      • 9.3.3.4. Nucleic Acid-based Drugs
    • 9.3.4. Rare Diseases
      • 9.3.4.1. Small Molecules
      • 9.3.4.2. Protein-based Therapeutics
      • 9.3.4.3. Cell Therapy
      • 9.3.4.4. Nucleic Acid-based Drugs
    • 9.3.5. Neurological Diseases
      • 9.3.5.1. Small Molecules
      • 9.3.5.2. Protein-based Therapeutics
      • 9.3.5.3. Cell Therapy
      • 9.3.5.4. Nucleic Acid-based Drugs
    • 9.3.6. Others
      • 9.3.6.1. Small Molecules
      • 9.3.6.2. Protein-based Therapeutics
      • 9.3.6.3. Cell Therapy
      • 9.3.6.4. Nucleic Acid-based Drugs
  • 9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
    • 9.4.1. Flow Cytometry
    • 9.4.2. Image-based Cytometry
    • 9.4.3. Biochemical Assays
    • 9.4.4. Mass Spectrometry
  • 9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
    • 9.5.1. Target Identification
    • 9.5.2. Hit Generation & Lead Identification
    • 9.5.3. Lead Optimization
    • 9.5.4. In Vitro Preclinical Studies
    • 9.5.5. In Vivo Preclinical Studies
    • 9.5.6. Clinical Studies

10. Europe Cell Analysis Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by End-user, 2017-2031
    • 10.2.1. Biotechnology & Pharmaceutical Companies
    • 10.2.2. Academia
    • 10.2.3. Cosmetic Industry
    • 10.2.4. Contract Research Organizations
    • 10.2.5. Contract Development and Manufacturing Organizations
  • 10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
    • 10.3.1. Oncology & Immune-oncology
      • 10.3.1.1. Small Molecules
      • 10.3.1.2. Protein-based Therapeutics
      • 10.3.1.3. Cell Therapy
      • 10.3.1.4. Nucleic Acid-based Drugs
    • 10.3.2. Cardiovascular & Metabolic Diseases
      • 10.3.2.1. Small Molecules
      • 10.3.2.2. Protein-based Therapeutics
      • 10.3.2.3. Cell Therapy
      • 10.3.2.4. Nucleic Acid-based Drugs
    • 10.3.3. Immunology
      • 10.3.3.1. Small Molecules
      • 10.3.3.2. Protein-based Therapeutics
      • 10.3.3.3. Cell Therapy
      • 10.3.3.4. Nucleic Acid-based Drugs
    • 10.3.4. Rare Diseases
      • 10.3.4.1. Small Molecules
      • 10.3.4.2. Protein-based Therapeutics
      • 10.3.4.3. Cell Therapy
      • 10.3.4.4. Nucleic Acid-based Drugs
    • 10.3.5. Neurological Diseases
      • 10.3.5.1. Small Molecules
      • 10.3.5.2. Protein-based Therapeutics
      • 10.3.5.3. Cell Therapy
      • 10.3.5.4. Nucleic Acid-based Drugs
    • 10.3.6. Others
      • 10.3.6.1. Small Molecules
      • 10.3.6.2. Protein-based Therapeutics
      • 10.3.6.3. Cell Therapy
      • 10.3.6.4. Nucleic Acid-based Drugs
  • 10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
    • 10.4.1. Flow Cytometry
    • 10.4.2. Image-based Cytometry
    • 10.4.3. Biochemical Assays
    • 10.4.4. Mass Spectrometry
  • 10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
    • 10.5.1. Target Identification
    • 10.5.2. Hit Generation & Lead Identification
    • 10.5.3. Lead Optimization
    • 10.5.4. In Vitro Preclinical Studies
    • 10.5.5. In Vivo Preclinical Studies
    • 10.5.6. Clinical Studies
  • 10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.6.1. EU5
    • 10.6.2. U.K.
    • 10.6.3. Switzerland
    • 10.6.4. Rest of Europe

11. China Cell Analysis Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by End-user, 2017-2031
    • 11.2.1. Biotechnology & Pharmaceutical Companies
    • 11.2.2. Academia
    • 11.2.3. Cosmetic Industry
    • 11.2.4. Contract Research Organizations
    • 11.2.5. Contract Development and Manufacturing Organizations
  • 11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
    • 11.3.1. Oncology & Immune-oncology
      • 11.3.1.1. Small Molecules
      • 11.3.1.2. Protein-based Therapeutics
      • 11.3.1.3. Cell Therapy
      • 11.3.1.4. Nucleic Acid-based Drugs
    • 11.3.2. Cardiovascular & Metabolic Diseases
      • 11.3.2.1. Small Molecules
      • 11.3.2.2. Protein-based Therapeutics
      • 11.3.2.3. Cell Therapy
      • 11.3.2.4. Nucleic Acid-based Drugs
    • 11.3.3. Immunology
      • 11.3.3.1. Small Molecules
      • 11.3.3.2. Protein-based Therapeutics
      • 11.3.3.3. Cell Therapy
      • 11.3.3.4. Nucleic Acid-based Drugs
    • 11.3.4. Rare Diseases
      • 11.3.4.1. Small Molecules
      • 11.3.4.2. Protein-based Therapeutics
      • 11.3.4.3. Cell Therapy
      • 11.3.4.4. Nucleic Acid-based Drugs
    • 11.3.5. Neurological Diseases
      • 11.3.5.1. Small Molecules
      • 11.3.5.2. Protein-based Therapeutics
      • 11.3.5.3. Cell Therapy
      • 11.3.5.4. Nucleic Acid-based Drugs
    • 11.3.6. Others
      • 11.3.6.1. Small Molecules
      • 11.3.6.2. Protein-based Therapeutics
      • 11.3.6.3. Cell Therapy
      • 11.3.6.4. Nucleic Acid-based Drugs
  • 11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
    • 11.4.1. Flow Cytometry
    • 11.4.2. Image-based Cytometry
    • 11.4.3. Biochemical Assays
    • 11.4.4. Mass Spectrometry
  • 11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
    • 11.5.1. Target Identification
    • 11.5.2. Hit Generation & Lead Identification
    • 11.5.3. Lead Optimization
    • 11.5.4. In Vitro Preclinical Studies
    • 11.5.5. In Vivo Preclinical Studies
    • 11.5.6. Clinical Studies

12. Rest of the World Cell Analysis Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by End-user, 2017-2031
    • 12.2.1. Biotechnology & Pharmaceutical Companies
    • 12.2.2. Academia
    • 12.2.3. Cosmetic Industry
    • 12.2.4. Contract Research Organizations
    • 12.2.5. Contract Development and Manufacturing Organizations
  • 12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
    • 12.3.1. Oncology & Immune-oncology
      • 12.3.1.1. Small Molecules
      • 12.3.1.2. Protein-based Therapeutics
      • 12.3.1.3. Cell Therapy
      • 12.3.1.4. Nucleic Acid-based Drugs
    • 12.3.2. Cardiovascular & Metabolic Diseases
      • 12.3.2.1. Small Molecules
      • 12.3.2.2. Protein-based Therapeutics
      • 12.3.2.3. Cell Therapy
      • 12.3.2.4. Nucleic Acid-based Drugs
    • 12.3.3. Immunology
      • 12.3.3.1. Small Molecules
      • 12.3.3.2. Protein-based Therapeutics
      • 12.3.3.3. Cell Therapy
      • 12.3.3.4. Nucleic Acid-based Drugs
    • 12.3.4. Rare Diseases
      • 12.3.4.1. Small Molecules
      • 12.3.4.2. Protein-based Therapeutics
      • 12.3.4.3. Cell Therapy
      • 12.3.4.4. Nucleic Acid-based Drugs
    • 12.3.5. Neurological Diseases
      • 12.3.5.1. Small Molecules
      • 12.3.5.2. Protein-based Therapeutics
      • 12.3.5.3. Cell Therapy
      • 12.3.5.4. Nucleic Acid-based Drugs
    • 12.3.6. Others
      • 12.3.6.1. Small Molecules
      • 12.3.6.2. Protein-based Therapeutics
      • 12.3.6.3. Cell Therapy
      • 12.3.6.4. Nucleic Acid-based Drugs
  • 12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
    • 12.4.1. Flow Cytometry
    • 12.4.2. Image-based Cytometry
    • 12.4.3. Biochemical Assays
    • 12.4.4. Mass Spectrometry
  • 12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
    • 12.5.1. Target Identification
    • 12.5.2. Hit Generation & Lead Identification
    • 12.5.3. Lead Optimization
    • 12.5.4. In Vitro Preclinical Studies
    • 12.5.5. In Vivo Preclinical Studies
    • 12.5.6. Clinical Studies